In our study investigating the effects of MIA-602 on HCC-1806 and MX-1 human triple negative breast cancers xenografted into nude mice, MIA-602 treatment at a concentration of 5 μg/day for 5 weeks significantly inhibited mean tumor volume of HCC-1806 tumors and of MX-1 tumors compared to controls [15]. Here, MX1 is linked to triple-negative breast carcinoma.